Cost-effectiveness analysis of ibrutinib plus venetoclax for relapsed or refractory mantle cell lymphoma in China and the United States
Bibliographic Data
| ID | 22066967 |
|---|---|
| Authors | Jing He (0000-0002-1954-2892, University of Electronic Science and Technology of China), Xianxi Liu (Chengdu Medical College), Qing Yang (0000-0001-6621-080X, Sichuan Cancer Hospital, corresponding author) |
| Year | 2026 |
| Volume | 14 |
| Pages | 1817037-1817037 |
| Publication date | 2026-05-21 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2026.1817037 |
| PMID | 42254648 |
| OpenAlex | W7161949509 |
| Language | EN |
| References cited | 42 |
Background: The SYMPATICO trial demonstrated that ibrutinib combined with venetoclax significantly improved progression-free survival in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). This study evaluated the cost-effectiveness of the combination of ibrutinib-venetoclax for R/R MCL from the healthcare perspectives of China and the United States (US). Methods: A partitioned survival model with a 35-year simulation time horizon was developed to compare the cost-effectiveness of ibrutinib-venetoclax versus ibrutinib-placebo. Primary outcomes included total costs, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). The robustness of the model was evaluated through one-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA). Results: Base-case analysis showed that the ICER of ibrutinib-venetoclax versus ibrutinib-placebo was $128,183.93/QALY in China, which was significantly higher than the willingness-to-pay (WTP) threshold of $40,334/QALY. It was still not cost-effective below the $150,000/QALY WTP threshold in the US, with an ICER of $951,082.87/QALY. OWSA demonstrated the robustness of the model. PSA showed that ibrutinib-venetoclax had a 0% probability of being cost-effective under the current WTP thresholds in China and the US. Price reduction analysis indicated that in China, reducing the price of venetoclax to 20% of its original cost could achieve cost-effectiveness with a 60.80% probability. In the US, a combined price reduction of ibrutinib and venetoclax to 22.53% of their original costs is necessary to achieve a 50% probability of cost-effectiveness. Conclusion: Ibrutinib-venetoclax is unlikely to be cost-effective versus ibrutinib-placebo for R/R MCL in both China and the US
Clinical trial · Ibrutinib · Lymphoma · Mantle cell lymphoma · Venetoclax · CAR-T cell therapy research · Chronic Lymphocytic Leukemia Research · Lymphoma Diagnosis and Treatment
| Highly cited | No |
|---|